Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K
Pfizer Inc, Groton, Connecticut, USA.
Quantitative Solutions Inc., Menlo Park, California, USA.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.
Aggregate data model-based meta-analysis is a regression approach to compare the dose-response and/or time-course across different treatments using summary level data from the literature. Literature search and systematic review following the Cochrane approach yielded 912 sources for investigational and approved treatments for psoriasis. In addition, data for tofacitinib were obtained from an internal database. Tofacitinib is an oral Janus kinase inhibitor. Two mathematical models were developed for Psoriasis Area and Severity Index (PASI) response in moderate to severe psoriasis patients to quantify the time to maximum effect for PASI75 and to evaluate the dose-response relationship for PASI responders (PASI50, PASI75, PASI90, PASI100) at Week 12. Body weight exhibited an inverse effect on the placebo component of both models, suggesting that body weight affects the overall PASI response regardless of drug. This analysis provides a quantitative framework for efficacy comparisons across psoriasis treatments.
基于汇总数据模型的荟萃分析是一种回归方法,用于使用文献中的汇总水平数据比较不同治疗方法的剂量反应和/或时间进程。按照Cochrane方法进行文献检索和系统评价,获得了912篇关于银屑病研究性治疗和批准治疗的文献来源。此外,托法替布的数据来自内部数据库。托法替布是一种口服Janus激酶抑制剂。针对中度至重度银屑病患者的银屑病面积和严重程度指数(PASI)反应,开发了两个数学模型,以量化达到PASI75最大疗效的时间,并评估第12周时PASI反应者(PASI50、PASI75、PASI90、PASI100)的剂量反应关系。体重对两个模型的安慰剂成分均有反向影响,表明体重无论药物如何都会影响总体PASI反应。该分析为银屑病治疗的疗效比较提供了一个定量框架。